MA71558A - Solutions pharmaceutiques d'anticorps anti-n3 pglu a beta et leurs utilisations - Google Patents

Solutions pharmaceutiques d'anticorps anti-n3 pglu a beta et leurs utilisations

Info

Publication number
MA71558A
MA71558A MA71558A MA71558A MA71558A MA 71558 A MA71558 A MA 71558A MA 71558 A MA71558 A MA 71558A MA 71558 A MA71558 A MA 71558A MA 71558 A MA71558 A MA 71558A
Authority
MA
Morocco
Prior art keywords
pglu
pharmaceutical solutions
beta antibodies
antibodies
beta
Prior art date
Application number
MA71558A
Other languages
English (en)
Inventor
Vincent John Corvari
Nicole H. DURBIN
Anant Navanithan Sharma
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of MA71558A publication Critical patent/MA71558A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA71558A 2022-07-21 2023-07-20 Solutions pharmaceutiques d'anticorps anti-n3 pglu a beta et leurs utilisations MA71558A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263369033P 2022-07-21 2022-07-21
PCT/US2023/070540 WO2024020470A1 (fr) 2022-07-21 2023-07-20 SOLUTIONS PHARMACEUTIQUES D'ANTICORPS ANTI-N3PGLU Aβ ET LEURS UTILISATIONS
EP23755273.2A EP4558166A1 (fr) 2022-07-21 2023-07-20 Solutions pharmaceutiques d'anticorps anti-n3 pglu a beta et leurs utilisations

Publications (1)

Publication Number Publication Date
MA71558A true MA71558A (fr) 2025-05-30

Family

ID=87576063

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71558A MA71558A (fr) 2022-07-21 2023-07-20 Solutions pharmaceutiques d'anticorps anti-n3 pglu a beta et leurs utilisations

Country Status (18)

Country Link
EP (1) EP4558166A1 (fr)
JP (1) JP2025525587A (fr)
KR (1) KR20250037554A (fr)
CN (1) CN119604302A (fr)
AR (1) AR129994A1 (fr)
AU (1) AU2023309007A1 (fr)
CA (1) CA3261418A1 (fr)
CL (1) CL2025000145A1 (fr)
CO (1) CO2025000508A2 (fr)
CR (1) CR20250023A (fr)
DO (1) DOP2025000005A (fr)
IL (1) IL318102A (fr)
JO (1) JOP20250013A1 (fr)
MA (1) MA71558A (fr)
MX (1) MX2025000820A (fr)
PE (1) PE20250785A1 (fr)
TW (1) TW202421188A (fr)
WO (1) WO2024020470A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie

Also Published As

Publication number Publication date
PE20250785A1 (es) 2025-03-14
DOP2025000005A (es) 2025-02-28
CO2025000508A2 (es) 2025-02-04
WO2024020470A1 (fr) 2024-01-25
JP2025525587A (ja) 2025-08-05
JOP20250013A1 (ar) 2025-01-21
CA3261418A1 (fr) 2024-01-25
AU2023309007A1 (en) 2025-01-30
CR20250023A (es) 2025-02-17
AR129994A1 (es) 2024-10-23
CN119604302A (zh) 2025-03-11
TW202421188A (zh) 2024-06-01
MX2025000820A (es) 2025-03-07
IL318102A (en) 2025-02-01
KR20250037554A (ko) 2025-03-17
EP4558166A1 (fr) 2025-05-28
CL2025000145A1 (es) 2025-05-30

Similar Documents

Publication Publication Date Title
EP4200335A4 (fr) Compositions d'anticorps anti-cd5 et leurs utilisations
EP4388009A4 (fr) Anticorps anti-ccr8 et leurs utilisations
MA56074A (fr) Anticorps contre le sars-cov-2 et leurs procédés d'utilisation
EP4100439A4 (fr) Nouveaux anticorps anti-lilrb2 et leurs utilisations
EP4267134A4 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de kras g12c et utilisations d'un inhibiteur de kras g12c pour le traitement de cancers
EP4132974A4 (fr) Anticorps anti-cd98 et leurs utilisations
MA52390A (fr) Anticorps anti-coronavirus et procédés d'utilisation
EP4103539A4 (fr) Composés et leurs utilisations pharmaceutiques
EP4161582A4 (fr) Conjugués anticorps-médicament contenant un anticorps anti-mésothéline et leurs utilisations
EP3917564A4 (fr) Anticorps anti-claudine 18 et leurs méthodes d'utilisation
EP4095148A4 (fr) Conjugué anticorps anti-trop-2-analogue d'exatécan et son utilisation médicale
EP4243938A4 (fr) Anticorps multispécifiques et leurs utilisations
EP4215549A4 (fr) Anticorps bispécifique anti-4-1bb-anti-pd-l1, composition pharmaceutique et utilisation associées
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
EP4174091A4 (fr) Anticorps monocaténaire anti-cd44 et son utilisation dans la préparation d'un médicament pour le traitement d'une tumeur
EP3995496A4 (fr) Médicament de camptothécine et un conjugué d'anticorps de celui-ci
MA71558A (fr) Solutions pharmaceutiques d'anticorps anti-n3 pglu a beta et leurs utilisations
EP4271484A4 (fr) Anticorps dirigés contre tnfr2 et leurs utilisations
EP4126245A4 (fr) Anticorps anti-cd33 et leurs utilisations
CA3242833A1 (fr) Compositions pharmaceutiques ophtalmiques et leurs utilisations
MA37317B1 (fr) Formulation d'anticorps il-17
EP4269435A4 (fr) Anticorps anti-b7-h3 et ses utilisations
EP4281474A4 (fr) Anticorps à liaison double, procédés de production d'anticorps à liaison double et leurs utilisations
EP4448008A4 (fr) Anticorps dirigés contre la calréticuline mutante et leurs utilisations
EP4253414A4 (fr) Anticorps anti-tigit, composition pharmaceutique et utilisation correspondante